biloroxazine

Search documents
Reviva Pharmaceuticals Holdings (RVPH) Update / Briefing Transcript
2025-06-02 13:00
Reviva Pharmaceuticals Holdings (RVPH) Update Summary Company Overview - Reviva Pharmaceuticals is a late-stage pharmaceutical company focused on developing next-generation therapies for central nervous system, respiratory, and metabolic diseases using chemical genomics-driven technologies [3][2]. Key Points from the Call Clinical Trials and Drug Development - Reviva is presenting results from the Phase 3 RECOVER trial, which focuses on the long-term safety, tolerability, and efficacy of viloroxazine in treating schizophrenia [11][12]. - The RECOVER trial included nearly 1,000 patients across multiple studies, demonstrating a differentiated clinical profile for viloroxazine [11]. - The drug showed strong efficacy in both acute and stable schizophrenia, with over 50% better adherence outcomes compared to historical data [12][11]. Efficacy Results - The efficacy of viloroxazine was highlighted, showing significant improvements in both positive and negative symptoms of schizophrenia, with effect sizes for PANSS total and positive symptoms being notably large [20][22]. - The drug demonstrated sustained decreases in psychopathology over a one-year period, with substantial improvements in negative symptoms and social cognition [27][30][33]. - The open-label extension trial indicated that patients experienced a 46.1% decrease in symptoms for the 15 mg dose and a 49.6% decrease for the 50 mg dose over the trial period [28]. Safety and Tolerability - The discontinuation rate due to adverse effects was low at 16% for viloroxazine compared to 22% for placebo, indicating good tolerability [20][44]. - Common side effects included somnolence and headache, with no significant extrapyramidal symptoms reported [45][69]. - The drug showed a weight gain of only 1.2 kg over 13 months, indicating a weight-neutral effect, which is a significant improvement over other atypical antipsychotics [52][70]. Metabolic Profile - Viloroxazine demonstrated reductions in cholesterol and LDL levels, suggesting a favorable metabolic profile compared to existing treatments [53][70]. - The drug also showed a significant reduction in prolactin levels, which is often elevated in patients taking other antipsychotics, potentially improving sexual function [57][71]. Neuroinflammation and Biomarkers - The drug's effects on neuroinflammatory markers were noted, with significant reductions in interleukins and TNF-alpha, suggesting a broad anti-inflammatory effect that may contribute to its efficacy in treating schizophrenia [63][65]. - Improvements in brain-derived neurotrophic factor (BDNF) levels were also reported, which is associated with better neuronal signaling and recovery from damage [64]. Additional Insights - The call emphasized the importance of addressing both positive and negative symptoms in schizophrenia treatment, with viloroxazine showing robust efficacy in both areas [74][76]. - The potential for viloroxazine to improve quality of life and functioning in patients with schizophrenia was highlighted, with suggestions that it could be effective in both acute and chronic settings [35][36]. Conclusion - Reviva Pharmaceuticals is advancing its clinical development of viloroxazine, which shows promise as a treatment for schizophrenia with a favorable safety and efficacy profile compared to existing therapies. The drug's ability to address both positive and negative symptoms, along with its favorable metabolic effects, positions it as a potential next-generation antipsychotic [35][71].
Reviva Pharmaceuticals Holdings (RVPH) 2025 Conference Transcript
2025-05-08 15:30
Summary of Reviva Pharmaceuticals Holdings (RVPH) Conference Call Company Overview - Reviva Pharmaceuticals is a clinical stage pharmaceutical company focused on developing novel therapies for neuropsychiatric diseases, particularly schizophrenia [3][38]. Pipeline and Development - The company has two molecules in development, with biloroxazine being the most advanced, currently in phase three studies for schizophrenia. Over one thousand patients have been treated [3][38]. - Enrollment for a long-term safety study is expected to complete in the next two to four weeks, with full data readout anticipated [3][38]. Core Insights on Schizophrenia - Schizophrenia is characterized by multiple symptom domains: positive, negative, mood, and cognitive symptoms. Most approved antipsychotics primarily address positive symptoms, leaving a significant unmet need for negative symptom treatment and treatment adherence [5][40]. - Neuroinflammation has gained attention as a contributing factor to schizophrenia, with approximately 30% of patients not responding to current treatments [6][40]. Efficacy and Safety Data - Biloroxazine shows a statistically significant efficacy with a ten-point separation from placebo in phase three trials, outperforming other antipsychotics like olanzapine and CAPLYTA [7][8]. - The drug demonstrates robust activity for negative symptoms, a critical area where most antipsychotics show limited efficacy [8][9]. - The discontinuation rate for biloroxazine is reported at 16%, significantly lower than the 30-45% range seen with other antipsychotics [11][13]. - Safety data indicates a clean profile with no significant movement disorders observed, which is a common side effect of other treatments [12][18]. Mechanism of Action - Biloroxazine modulates dopamine and serotonin receptors and has potent activity against neuroinflammatory targets, differentiating it from other antipsychotics [7][16]. - The drug's unique mechanism may enhance efficacy while mitigating side effects, particularly motor side effects [17][19]. Future Development Plans - Beyond schizophrenia, Reviva plans to explore indications for bipolar disorder, major depressive disorder, and ADHD, leveraging the drug's safety profile and efficacy in treating negative symptoms [34][39]. - The ADHD market is estimated at $28 billion, with no new drugs currently in development, presenting a significant opportunity for Reviva [34]. Market Positioning - The company believes biloroxazine will be a differentiated product in the treatment landscape, especially as it addresses both positive and negative symptoms effectively [32][33]. - The drug's development is positioned against both older generic drugs and newer mechanisms, emphasizing the need for effective treatment of negative symptoms [31][32]. Regulatory Pathway - Reviva has engaged with the FDA regarding the phase three study data and plans to conduct a pre-NDA meeting as full data readout approaches [26][27]. Conclusion - Reviva Pharmaceuticals is optimistic about biloroxazine's potential for NDA approval within the next 18 to 24 months, with a strong focus on addressing unmet needs in schizophrenia and expanding into other neuropsychiatric conditions [14][34].